CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration

Hartley, Christopher; Vaughan, James; Jarzembowski, Jason A.; Kroft, Steven H.; Hosking, Paul; Harrington, Alexandra M.; Olteanu, Horatiu

doi:10.1093/ajcp/aqx097

Cited by 9 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this nation-wide case series of 50 PTLDs after solid organ transplantation, 70% of the PTLDs expressed CD30 in the tumor cells and were thus potentially treatable with brentuximab vedotin. Previous case series have reported that 79-87% of the PTLDs were CD30þ [16][17][18]. In line with previous studies, we found that all Hodgkin lymphomas and polymorphic PTLDs and a vast majority of non-GC-type of DLBCLs and T-cell PTLDs were CD30þ, whereas GC-type of DLBCLs and Burkitt lymphomas were all CD30- [16,17,[23][24][25].…”

Section: Discussionsupporting

confidence: 91%

“…In line with previous studies, we found that all Hodgkin lymphomas and polymorphic PTLDs and a vast majority of non-GC-type of DLBCLs and T-cell PTLDs were CD30þ, whereas GC-type of DLBCLs and Burkitt lymphomas were all CD30- [16,17,[23][24][25]. Furthermore, CD30þ PTLDs have been associated with EBVpositivity by EBER ISH [16][17][18]. We saw a trend that CD30þ PTLDs were more frequently EBVþ either when analyzed by EBER ISH or by LMP-1 IHC but numbers were too small to prove an association.…”

Section: Discussionsupporting

confidence: 91%

“…We saw a trend that CD30þ PTLDs were more frequently EBVþ either when analyzed by EBER ISH or by LMP-1 IHC but numbers were too small to prove an association. We report for the first time that CD30þ PTLDs occur significantly earlier post-transplant than CD30cases, which was seen previously as a trend in a study by Hartley et al [18].…”

Section: Discussionsupporting

confidence: 85%

“…The highest CD30 expression is found in classical Hodgkin lymphoma and ALCL, but CD30 is expressed at lower levels in a subset of other T-and B-cell lymphomas, notably EBVþ diffuse large B-cell lymphoma (DLBCL) and PTLD [14,15]. Approximately 80-90% of PTLDs were reported to express CD30 in previous case series [16][17][18]. There is not a clear correlation between antitumor effect of brentuximab vedotin and expression of CD30 in lymphoma tissue but a minimum expression threshold appears to be required for antitumor activity [7,19].…”

Section: Introductionmentioning

confidence: 99%

“…Besides being a potential predictive biomarker for response to brentuximab vedotin, expression of CD30 has been reported to be a favorable prognostic marker for both de novo DLBCL and PTLD [15,16]. Furthermore, an association between higher frequency of intratumoral regulatory T-cells (Tregs) and CD30 expression in PTLD was recently reported [18].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

CD30 expression and survival in posttransplant lymphoproliferative disorders

et al. 2020

View full text Add to dashboard Cite

Background: Post-transplant lymphoproliferative disorder (PTLD) is a rare but life-threatening complication of transplantation. For refractory and relapsed PTLD new therapies are needed, such as the antibody-drug conjugate brentuximab vedotin that targets CD30. There is limited knowledge of CD30 expression in various subtypes of PTLD and its correlation to clinicopathological features. Therefore, we studied the expression of CD30 in PTLD following solid organ transplantation and correlated CD30 expression to PTLD subtype, Epstein-Barr virus (EBV)-status, intratumoral regulatory T-cells (Tregs), clinical features, and outcome. Methods: We included 50 cases of PTLD from a nationwide study of PTLDs following solid organ transplantation in Sweden. The tumor biopsies were reevaluated, and clinical data were collected. CD30 expression on tumor cells was analyzed by immunohistochemistry with the clone Ber-H2. Thirtyone cases were stained with clone 236 A/E7 for detection of forkhead box protein 3 (FoxP3, a Treg biomarker). Results: The case series consisted of 6% polymorphic, 88% monomorphic, and 6% Hodgkin lymphoma-like PTLDs and 53% of the cases were EBVþ. Overall, 70% (35/50) of the PTLDs were CD30þ (1% CD30þ tumor cells) and 30% (15/50) were CD30-. All polymorphic PTLDs (n ¼ 3) and Hodgkin lymphomas (n ¼ 3), 88% (14/16) of non-germinal center type of diffuse large B-cell lymphoma (DLBCL), and 75% (9/12) of T-cell PTLDs were CD30þ whereas all germinal center-type of DLBCL (n ¼ 5) and Burkitt type PTLD (n ¼ 2) were CD30-. CD30þ PTLD tended to be EBVþ more frequently (p ¼ .07) and occurred earlier posttransplant (2.1 vs. 8.2 years, p ¼ .01) than CD30-PTLD. Type of transplant and localization of the tumor did not differ between the groups except that CNS engagement was more common in CD30-PTLD (p ¼ .02). CD30-status was not associated with presence of intratumoral Tregs or overall survival. Conclusion: Expression of CD30 varied with PTLD subtype. There was no association between CD30 and survival, regardless of subtype.

show abstract